Adults 20 to 60, any sex, with Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Maximal Glucagon Concentration During HypoglycemiaPrimary· Day 14, Day 42
Maximal glucagon concentration during insulin induced hypoglycemia. This was measured during the hypoglycemic steady state of the hyper-insulinemic euglycemic-hypoglycemic clamp study.
Group
Value
95% CI
T1D on MBX-2982
19.9
± 12.6
T1D on Placebo
22.5
± 16.8
Healthy Normal Volunteers
82.7
± 39.7
Total Area Under the Curve (AUC) for Glucagon During Hypoglycemia.Primary· Day 14, Day 42
This outcome was measured during the hypoglycemic steady state of the hyper-insulinemic euglycemic hypoglycemic clamp study. Total area under the curve (AUC) for glucagon was measured during the time points of 120 minutes to 140 minutes of the clamp.
Group
Value
95% CI
T1D on MBX-2982
6624.6
± 3772.4
T1D on Placebo
6037.5
± 3545.9
Healthy Normal Volunteers
15923.2
± 5350.6
Incremental AUC for Glucagon During Hypoglycemia (Above Baseline Levels During Euglycemia)Primary· Day 14, Day 42
This is the difference between the AUC during the hypoglycemic steady state (time points 120 - 140 mins of clamp) and the baseline glucagon levels during euglycemic steady state (timepoints 60 min - 80 mins of the clamp)
Group
Value
95% CI
T1D on MBX-2982
327.9
± 257.9
T1D on Placebo
467.8
± 435.7
Healthy Normal Volunteers
2445.4
± 1346.4
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events were collected from screening visit till end of study (day 49)..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to test if a specific research medication could increase the response to low blood glucose in people with type 1 diabetes. The response of the body to low blood sugar will be measured in healthy people as a reference point.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AdventHealth Translational Research Institute
Last refreshed: 17 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04432090.